Epigenetic Mechanisms and Events in Gastric Cancer-Emerging Novel Biomarkers

Overview

Journal Pathol Oncol Res

Specialty Oncology

Date 2018 Mar 20

PMID 29552712

Citations 31

Authors

Puneet

Hasan Raza Kazmi

Soni Kumari

Satendra Tiwari

A Khanna

Gopeshwar Narayan

Affiliations

Soon will be listed here.

Abstract

Gastric cancer is one of the most common malignancy worldwide. The various genetic and epigenetic events have been found to be associated with its carcinogenesis. The epigenetic is a heritable and transient/reversible change in the gene expression that is not accompanied by modification in the DNA sequence. This event is characterized by the alteration in the promoter CpG island of the gene or histone modification. These events are associated with silencing of critical tumor suppressor gene and activation of oncogenes leading to carcinogenesis. The DNA methylation is a chemical change in the DNA sequence that most commonly occurs at cytosine moiety of CpG dinucleotide and histone, primarily on N- terminal tail that ultimately effect the interaction of DNA with chromatin modifying protein.Hypermethylation of tumor suppressor genes and global hypomethylation of oncogenes are widely studied epigenetic modifications. There are large number of publish reports regarding epigenetic events involving gastric cancer. These changes are potentially useful in identifying markers for early diagnosis and management of this lethal malignancy. Also, role of specific miRNAs and long non coding RNAs in regulation of gene expression is gaining interest and is a matter of further investigation. In this review, we aimed to summarize major epigenetic events (DNA methylation) in gastric cancer along with alteration in miRNAs and long non coding RNAs which plays an important role in pathology of this poorly understood malignancy.

Citing Articles

Modelling of miRNA-mRNA Network to Identify Gene Signatures with Diagnostic and Prognostic Value in Gastric Cancer: Evidence from and Studies.

Jahantab M, Salehi M, Koushki M, Farrokhi Yekta R, Amiri-Dashatan N, Rezaei-Tavirani M Rep Biochem Mol Biol. 2025; 13(2):281-300.

PMID: 39995653 PMC: 11847593. DOI: 10.61186/rbmb.13.2.281.

Exploring the Complexity of Pan-Cancer: Gene Convergences and in silico Analyses.

Teodoro L, Carreira A, Sogayar M Breast Cancer (Dove Med Press). 2024; 16:913-934.

PMID: 39691553 PMC: 11651076. DOI: 10.2147/BCTT.S489246.

Lack of Association Between BsmI and FokI Polymorphisms of the VDR Gene and Sporadic Colorectal Cancer in a Romanian Cohort-A Preliminary Study.

Petre-Mandache B, Burada E, Cucu M, Atasie D, Riza A, Streata I Curr Oncol. 2024; 31(10):6406-6418.

PMID: 39451780 PMC: 11505952. DOI: 10.3390/curroncol31100476.

Transcriptional and Epigenetic Bioinformatic Analysis of Claudin-9 Regulation in Gastric Cancer.

Hernandez-Nava E, Montano L, Rendon-Huerta E J Oncol. 2024; 2021:5936905.

PMID: 39296813 PMC: 11410435. DOI: 10.1155/2021/5936905.

Gastric Cancer in the Era of Epigenetics.

Christodoulidis G, Koumarelas K, Kouliou M, Thodou E, Samara M Int J Mol Sci. 2024; 25(6).

PMID: 38542354 PMC: 10970362. DOI: 10.3390/ijms25063381.

References

Becker K, Atkinson M, Reich U, Becker I, Nekarda H, Siewert J . E-cadherin gene mutations provide clues to diffuse type gastric carcinomas. Cancer Res. 1994; 54(14):3845-52. View

Koga Y, Kitajima Y, Miyoshi A, Sato K, Sato S, Miyazaki K . The significance of aberrant CHFR methylation for clinical response to microtubule inhibitors in gastric cancer. J Gastroenterol. 2006; 41(2):133-9. DOI: 10.1007/s00535-005-1732-7. View

Cheng Y, Yu J, Wong Y, Man E, To K, Jin V . Frequent epigenetic inactivation of secreted frizzled-related protein 2 (SFRP2) by promoter methylation in human gastric cancer. Br J Cancer. 2007; 97(7):895-901. PMC: 2360406. DOI: 10.1038/sj.bjc.6603968. View

Cao W, Wu H, He B, Zhang Y, Zhang Z . Analysis of long non-coding RNA expression profiles in gastric cancer. World J Gastroenterol. 2013; 19(23):3658-64. PMC: 3691033. DOI: 10.3748/wjg.v19.i23.3658. View

Carninci P, Kasukawa T, Katayama S, Gough J, Frith M, Maeda N . The transcriptional landscape of the mammalian genome. Science. 2005; 309(5740):1559-63. DOI: 10.1126/science.1112014. View

Windle J, Prystowsky E, Miles W, Heger J . Pharmacokinetic and electrophysiologic interactions of amiodarone and procainamide. Clin Pharmacol Ther. 1987; 41(6):603-10. DOI: 10.1038/clpt.1987.82. View

Hayashi K, Yokozaki H, Goodison S, Oue N, Suzuki T, Lotan R . Inactivation of retinoic acid receptor beta by promoter CpG hypermethylation in gastric cancer. Differentiation. 2001; 68(1):13-21. DOI: 10.1046/j.1432-0436.2001.068001013.x. View

Ono S, Oue N, Kuniyasu H, Suzuki T, Ito R, Matsusaki K . Acetylated histone H4 is reduced in human gastric adenomas and carcinomas. J Exp Clin Cancer Res. 2002; 21(3):377-82. View

Poplawski T, Tomaszewska K, Galicki M, Morawiec Z, Blasiak J . Promoter methylation of cancer-related genes in gastric carcinoma. Exp Oncol. 2008; 30(2):112-6. View

10.

Oshimo Y, Oue N, Mitani Y, Nakayama H, Kitadai Y, Yoshida K . Frequent epigenetic inactivation of RIZ1 by promoter hypermethylation in human gastric carcinoma. Int J Cancer. 2004; 110(2):212-8. DOI: 10.1002/ijc.20090. View

11.

Strolin Benedetti M, Rumigny J, Dostert P . [Mechanisms of action and biochemical toxicology of valproic acid]. Encephale. 1984; 10(4):177-88. View

12.

Karpf A, Jones D . Reactivating the expression of methylation silenced genes in human cancer. Oncogene. 2002; 21(35):5496-503. DOI: 10.1038/sj.onc.1205602. View

13.

Li C, Liang G, Yao W, Sui J, Shen X, Zhang Y . Integrated analysis of long non-coding RNA competing interactions reveals the potential role in progression of human gastric cancer. Int J Oncol. 2016; 48(5):1965-76. DOI: 10.3892/ijo.2016.3407. View

14.

Robertson K . DNA methylation and human disease. Nat Rev Genet. 2005; 6(8):597-610. DOI: 10.1038/nrg1655. View

15.

Kang G, Lee S, Kim J, Jung H . Profile of aberrant CpG island methylation along multistep gastric carcinogenesis. Lab Invest. 2003; 83(4):519-26. DOI: 10.1097/01.lab.0000064704.53132.65. View

16.

Sparmann A, van Lohuizen M . Polycomb silencers control cell fate, development and cancer. Nat Rev Cancer. 2006; 6(11):846-56. DOI: 10.1038/nrc1991. View

17.

Kim T, Lee H, Hwang K, Lee M, Kim J, Bang Y . Methylation of RUNX3 in various types of human cancers and premalignant stages of gastric carcinoma. Lab Invest. 2004; 84(4):479-84. DOI: 10.1038/labinvest.3700060. View

18.

Park W, Oh R, Park J, Lee S, Shin M, Kim Y . Frequent somatic mutations of the beta-catenin gene in intestinal-type gastric cancer. Cancer Res. 1999; 59(17):4257-60. View

19.

Oue N, Shigeishi H, Kuniyasu H, Yokozaki H, Kuraoka K, Ito R . Promoter hypermethylation of MGMT is associated with protein loss in gastric carcinoma. Int J Cancer. 2001; 93(6):805-9. DOI: 10.1002/ijc.1403. View

20.

Tahara E . Genetic pathways of two types of gastric cancer. IARC Sci Publ. 2004; (157):327-49. View